News ArchivesRead News

Your Weekly News Update for the Week of 1.6.20

Monday January 06, 2020
Parkinson’s Process Nipped in the RNA Bud
Genetic Engineering & Biotechnology News
Rather thα-synuclein be expressed the Scripps Research scientists, together with colleagues from other institutions, decided to nip it in the bud—the RNA bud. That is, the scientists chose to target the mRNA that encodes α-synuclein. Preventing mRNA from being processed by ribosomes, they discovered, is “cytoprotective.” Many undruggable proteins, Disney’s research suggests, are transcribed by RNA that do have stable structures, meaning the RNA should be druggable, offering an effective workaround.
“We are applying this across a number of disease indications, with our priority being applying these approaches to the diseases that have the most urgent medical need,” Disney said. Parkinson’s disease is clearly among them.
Parkinson’s Drug Can Also Curb Dementia’s Delusions, Researchers Find
Chicago Sun-Times
"A drug that curbs delusions in people with Parkinson’s did the same for people with Alzheimer’s and other forms of dementia in a study that was stopped early because the benefit seemed clear."
If regulators agree, the drug could become the first treatment specifically for dementia-related psychosis and the first new medicine for Alzheimer’s in nearly two decades. It targets some of the most troubling symptoms that patients and caregivers face — hallucinations that often lead to anxiety, aggression, and physical and verbal abuse.
Finding the Joy in 'Slow Parenting' With Parkinson's
"I knew parenting was going to be harder for me because of my Parkinson’s, but I really had no idea. It’s one of those things, you can never know what it is really like until you are in it. When I first held my son in my arms at 2:52 a.m. on that rainy July morning, my heart swelled with a love I had not known was there."